来源：光大证券微资讯 热点聚焦 1、隔夜，金、银在刷新历史高点后大幅回调。1月27日7:01，现货白银盘初涨1%，报104.7美元/盎司 （此前日内涨幅一度高达14%，最高触及117美元/盎司）。现货黄金涨0.3%，报5025美元/盎司（此前曾 上涨2.5%，最高报约5110美元/盎司）。 2、白宫宣布，因韩国国会迟迟未批准美韩贸易协议，他已决定将对韩国汽车、木材、制药产品以及其 他"对等关税"项目的税率从15%上调至25%。 3、隔夜，美股三大指数小幅收涨。纳斯达克中国金龙指数收跌0.62%。此前，美国稀土公司宣布，获 得美国政府16亿美元的资金支持，用于加速建设国内重稀土价值链。美股盘前，美国稀土公司股价一度 暴涨62%，随后涨幅收窄。英伟达与CoreWeave公司宣布扩大长期的互补合作关系，使CoreWeave能加 速到2030年建设超过5吉瓦的AI工厂，CoreWeave盘前股价一度拉涨9%。 4、哈萨克斯坦供应恢复抵消了美国暴风雪的影响，国际油价小幅下跌。而持续的严寒天气导致美国天 然气价格周一大幅上涨，主力期货合约一度突破7美元/百万英热，创下自2022年以来新高，最高涨幅达 39%，随后回落至约 ...

Industry News - The Ministry of Commerce announced plans to optimize the implementation of a trade-in program for consumer goods, promoting consumption of major durable goods such as home appliances [5] - The Ministry of Commerce aims to significantly develop service trade this year and will introduce policies to expand inbound consumption [5][6] - The China Banking and Insurance Regulatory Commission emphasized the need for proactive assessment of systemic financial risks and maintaining the stability of financial markets [6] - The China Automotive Industry Association held a meeting to discuss industry challenges including chip shortages and promoting consumption [7] - The Beijing Human-Robot Innovation Center successfully connected humanoid robots to low-orbit satellites, marking a global first in this technology [8] Company News - Yushutech announced its partnership as the robot collaborator for the 2026 Spring Festival Gala [9] - Tencent plans to distribute 1 billion yuan in cash for the Spring Festival, while Baidu will follow with a 500 million yuan cash giveaway [17] - Zijin Mining announced plans to acquire 100% of United Gold for 28 billion yuan [10] - *ST Tianshan announced that its stock may be delisted [10] - Dongfang Risheng expects a net loss of 2.3 to 2.9 billion yuan for 2025 [10] - Chunzhong Technology anticipates a net profit of 265 to 290 million yuan for 2025, a year-on-year increase of 209% to 238% [10] - China Rare Earth expects a net profit of 143 to 185 million yuan for 2025, indicating a turnaround from losses [10]

Group 1 - Evert plans to acquire equity in Shengpu Co., with stock suspension starting January 27, 2026, expected to last no more than 10 trading days [5] - Haike New Source signed a long-term cooperation agreement with BYD Lithium Battery to supply at least 100,000 tons of electrolyte solvent annually for three years [5] - Sanxiang Bio has developed a CE-certified Nipah virus nucleic acid testing kit and a domestic research version, responding to the Nipah virus outbreak in India [9][10] Group 2 - Sangfor Health expects a Q4 net profit of approximately 2.5 billion yuan, a 1097% increase from the previous quarter, driven by a significant payment from Pfizer for the 707 project [2] - Puran Co. anticipates a Q4 net profit of about 1.46 billion yuan, a 696% increase from Q3, despite an annual decrease of approximately 29.89% [3][4] - Chip Source Micro expects a net profit of 52 million to 76 million yuan for 2025, a decrease of 62.53% to 74.36% year-on-year due to increased costs and reduced other income [6] Group 3 - Maide Medical forecasts a net profit of approximately 66.5 million yuan for 2025, marking a turnaround from losses in the previous year [7] - Ruixin Micro expects a net profit of 1.023 billion to 1.103 billion yuan for 2025, representing a growth of 71.97% to 85.42% year-on-year [8] - Qingda Environmental anticipates a net profit of 165 million to 190 million yuan for 2025, an increase of 77.47% to 104.36% year-on-year [10] Group 4 - Jiangxun Technology expects a net profit increase of approximately 86.44% for 2025, reaching around 156 million yuan [11] - Micron Bio anticipates a net profit of approximately 53.5 million yuan for 2025, achieving profitability after previous losses [11] - Blue Special Optics forecasts a net profit of 375 million to 400 million yuan for 2025, a growth of 70.04% to 81.38% year-on-year [13]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301363 | 美好医疗 | 32.18 | -5.46% | 18.03万 | 5.96 Z | | 301093 | 不是股份 | 79.99 | -5.17% | 9.73万 | · 7.87亿 | | 688351 | 微电生理 | 24.55 | -5.10% | 9.77万 | 2.43 Z | | 688029 | 南微医学 | 81.25 | -4.96% | 4.46万 | 3.64亿 | | 300753 | 爰朋医疗 | 33.75 | -4.74% | 11.59万 | 3.94亿 | | 688068 | 热景生物 | 147.44 | -4.65% | 2.75万 | 4.05 Z | | 688217 | 睿昂基因 | 31.14 | -4.45% | 1.98万 | 6293.79万 | | 300246 | 宝莱特 | 13.79 | -4.44% | 18.01万 | 2.50亿 | | 688393 | 安必 ...

A股市场 生物医药股全线上涨，其中，康乐卫士涨超20%， 迈克生物、 凯普生物、 之江生物、 华兰疫 苗20CM涨停， 金迪克、 智飞生物涨超13%， 康希诺、 百普赛斯涨超12%， 东方生物涨超11%， 沃森 生物、 圣湘生物涨超10%， 达安基因、 科华生物10CM涨停， 康泰生物、 泓博医药涨超7%。 ...

Group 1 - The A-share market saw a significant rise in biopharmaceutical stocks, with notable increases such as Kanglaweishi up over 20% and several others reaching the daily limit of 20% [1] - The outbreak of Nipah virus in West Bengal, India, has prompted a response from local authorities, with nearly a hundred individuals under home quarantine due to the high mortality rate of up to 75% and the absence of a vaccine [1][2] - The Thai Civil Aviation Authority has announced comprehensive screening for flights from West Bengal starting January 26 to prevent the virus from entering Thailand [1] Group 2 - Historical context indicates that Nipah virus outbreaks have previously occurred in Malaysia, Singapore, India, Bangladesh, and the Philippines, resulting in significant fatalities and the culling of millions of pigs [2] - The World Health Organization classifies Nipah virus as a deadly zoonotic virus primarily carried by fruit bats, with a transmission rate through contaminated food or direct human-to-human contact [2] - The incubation period for Nipah virus ranges from 4 to 14 days, with a maximum of 45 days, and there are currently no specific vaccines or effective treatments available [2] Group 3 - The stock performance of various biopharmaceutical companies shows substantial year-to-date gains, with Kanglaweishi at 45.10%, Maike Biological at 26.90%, and Kaipu Biological at 34.76% [3] - Other companies such as Zhijiang Biological and Jindike also reported significant increases, with year-to-date growth rates of 26.67% and 18.44% respectively [3] - The overall market trend indicates a strong investor interest in biopharmaceutical stocks amid the health crisis related to the Nipah virus outbreak [1][3]

Group 1 - The A-share market saw a significant rise in biopharmaceutical stocks, with Kang Le Wei Shi increasing by over 20% and several other companies reaching their daily limit up of 20% [1] - The outbreak of Nipah virus in West Bengal, India, has led to a human-to-human transmission risk, with a mortality rate as high as 75% and no vaccine currently available [1][2] - The Thai Civil Aviation Authority has announced comprehensive screening for flights from West Bengal, India, starting January 26, to prevent the virus from entering Thailand [1] Group 2 - Historical context shows that Nipah virus outbreaks previously occurred in Malaysia and Singapore from 1998 to 1999, resulting in over a hundred deaths and the culling of a million pigs [2] - The World Health Organization classifies Nipah virus as a deadly zoonotic virus primarily carried by fruit bats, with a transmission potential through contaminated food or direct human contact [2] - The incubation period for Nipah virus ranges from 4 to 14 days, with a maximum of 45 days before symptoms appear [2] Group 3 - Notable stock performances include: - Kang Le Wei Shi: 20.48% increase, market cap of 3.371 billion - Mai Ke Biological: 20.03% increase, market cap of 8.586 billion - Kai Pu Biological: 20.03% increase, market cap of 4.687 billion - Zhi Jiang Biological: 20.01% increase, market cap of 4.910 billion - Jin Di Ke: 13.72% increase, market cap of 2.952 billion [3] - Other companies with significant increases include Zhi Fei Biological (13.31%), Kang Xi Nuo (12.77%), and Bai Pu Sai Si (12.01%) [3]

（文章来源：每日经济新闻） 每经AI快讯，1月26日，生物医药概念午后快速拉升，凯普生物直线涨停，沃森生物、圣湘生物、万泽 股份、智飞生物、君实生物跟涨。 ...

达安基因：公司此前表示已有尼帕病毒核酸检测的科研技术储备。 圣湘生物：此前表示推进亨尼帕病毒检测试剂的研发工作。 *免责声明：文章内容仅供参考，不构成投资建议 *风险提示：股市有风险，入市需谨慎 据环球时报报道，近日，印度西孟加拉邦暴发尼帕病毒疫情。 另据人民网，鉴于近期尼帕病毒（Nipah Virus）在印度出现传播风险，泰国清迈国际机场已全面升级对 国际入境旅客的健康筛查措施，以加强疫情监测与防控，防范病毒输入风险。 而智通财经介绍，世界卫生组织将尼帕病毒列为一种致命的人畜共患病毒，主要由果蝠携带。该病毒可 通过被污染的食物传播给人类，或直接人传人，死亡率在40%到75%之间。据世卫组织介绍，这种病毒 从感染到出现症状的潜伏期一般为4天至14天，最长可达45天。目前尚无专门针对尼帕病毒的疫苗和有 效疗法。 公司方面，据上市公司互动平台表示， ...

Core Viewpoint - Shengxiang Bio's stock price has shown fluctuations, with a recent decline of 2.04% and a total market value of 11.663 billion yuan, while the company has experienced a year-to-date stock price increase of 6.45% [1] Financial Performance - For the period from January to September 2025, Shengxiang Bio achieved operating revenue of 1.244 billion yuan, representing a year-on-year growth of 20.49%, while the net profit attributable to shareholders decreased by 2.10% to 191 million yuan [2] - Cumulatively, since its A-share listing, Shengxiang Bio has distributed a total of 2.363 billion yuan in dividends, with 967 million yuan distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Shengxiang Bio increased by 4.17% to 21,600, with an average of 26,772 circulating shares per person, which is a decrease of 4.01% [2] - Among the top ten circulating shareholders, Huabao Zhongzheng Medical ETF holds 9.8053 million shares, a decrease of 1.7872 million shares compared to the previous period, while Hong Kong Central Clearing Limited is a new shareholder with 3.6601 million shares [3] Business Overview - Shengxiang Bio, established on April 23, 2008, and listed on August 28, 2020, focuses on innovative gene technology, encompassing the research, production, and sales of diagnostic reagents and instruments, as well as third-party medical testing services [1] - The company's main revenue sources include diagnostic reagents (87.39%), diagnostic instruments (5.71%), testing services (4.55%), and other supplementary services (2.34%) [1]